Long-term follow-up results from clinical study of hetrombopag combined with cyclosporine a in the treatment of children with non-severe aplastic anemia
Efficacy and safety of hetrombopag in increasing platelet counts in patients with hepatocellular carcinoma undergoing hepatectomy: a randomized, placebo-controlled study
这是一项随机、双盲、安慰剂对照、单中心研究,旨在评估海曲泊帕治疗肝癌患者肝切除术前血小板减少症的有效性和安全性,主要研究终点为围手术期无需输注血小板或其他干预措施(rhTPO或IL-11)的患者比例。在2022年7月至2023年9月期间,共纳入22例患者,其中海曲泊帕组12例,安慰剂组10例。两组基线均衡可比。海曲泊帕组75%(9/12)的患者达到主要研究终点,显著高于安慰剂组的50%(5/10)(p=0.048)。海曲泊帕组肝切除术前血小板计数≥80×109/L的患者比例显著高于安慰剂组(75% vs. 10%,p=0.001)。海曲泊帕耐受性良好。
A single-arm, prospective, single-center clinical study on the use of hetrombopag for the prevention of consolidation chemotherapy-induced thrombocytopenia in acute leukemia
Efficacy and safety of hetrombopag for secondary prevention of chemotherapy-induced thrombocytopenia in patients with gynecological malignancies: a prospective, single-center, single-arm study
Combination of chemotherapy and mecapegfilgrastim for hematopoietic stem cell mobilization in lymphoma and multiple myeloma patients: a prospective, open-label, randomized study